BRPI0921392A2 - inibidores quinase com perfil de segurança cyp aperfeiçoado - Google Patents

inibidores quinase com perfil de segurança cyp aperfeiçoado

Info

Publication number
BRPI0921392A2
BRPI0921392A2 BRPI0921392A BRPI0921392A BRPI0921392A2 BR PI0921392 A2 BRPI0921392 A2 BR PI0921392A2 BR PI0921392 A BRPI0921392 A BR PI0921392A BR PI0921392 A BRPI0921392 A BR PI0921392A BR PI0921392 A2 BRPI0921392 A2 BR PI0921392A2
Authority
BR
Brazil
Prior art keywords
cypase
inhibitors
safety profile
improved cyp
cyp
Prior art date
Application number
BRPI0921392A
Other languages
English (en)
Inventor
Michael L Curtin
Michael R Michaelides
Robin R Frey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0921392A2 publication Critical patent/BRPI0921392A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0921392A 2008-12-05 2009-12-04 inibidores quinase com perfil de segurança cyp aperfeiçoado BRPI0921392A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12028108P 2008-12-05 2008-12-05
US22376009P 2009-07-08 2009-07-08
PCT/US2009/066725 WO2010065825A2 (en) 2008-12-05 2009-12-04 Kinase inhibitors with improved cyp safety profile

Publications (1)

Publication Number Publication Date
BRPI0921392A2 true BRPI0921392A2 (pt) 2016-04-26

Family

ID=41559043

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921392A BRPI0921392A2 (pt) 2008-12-05 2009-12-04 inibidores quinase com perfil de segurança cyp aperfeiçoado

Country Status (25)

Country Link
US (2) US20100144783A1 (pt)
EP (1) EP2373662B1 (pt)
JP (1) JP5588458B2 (pt)
KR (1) KR101639642B1 (pt)
CN (1) CN102239171B (pt)
AR (1) AR074481A1 (pt)
AU (1) AU2009322270B2 (pt)
BR (1) BRPI0921392A2 (pt)
CA (1) CA2743592A1 (pt)
CL (1) CL2011001312A1 (pt)
CO (1) CO6382131A2 (pt)
DO (1) DOP2011000153A (pt)
EC (1) ECSP11011172A (pt)
ES (1) ES2524966T3 (pt)
IL (1) IL212716A (pt)
MX (1) MX2011005943A (pt)
MY (1) MY179042A (pt)
NZ (1) NZ592714A (pt)
PA (1) PA8852401A1 (pt)
PE (1) PE20110830A1 (pt)
RU (2) RU2480472C2 (pt)
TW (2) TWI441827B (pt)
UA (1) UA103351C2 (pt)
UY (1) UY32291A (pt)
WO (1) WO2010065825A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
KR101639642B1 (ko) * 2008-12-05 2016-07-14 애브비 바하마스 리미티드 암 치료에 사용하기 위한 키나제 억제제로서의 티에노［3,2-ｃ］피리딘 유도체
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
TWI492949B (zh) 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
US8633317B2 (en) 2010-06-09 2014-01-21 Abbvie Inc. Crystalline salts of thieno[3,2-c]pyridine kinase inhibitors with improved cpy safety profile
KR20130109092A (ko) * 2010-06-09 2013-10-07 아보트 러보러터리즈 키나제 억제제를 함유하는 고체 분산물
US8911725B2 (en) 2010-06-23 2014-12-16 University Of Central Florida Research Foundation, Inc. Co-targeting of aurora A kinase and LIM kinase 1 for cancer therapy
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
AU2012352112A1 (en) 2011-12-14 2014-06-12 Abbvie Inc. Compositions containing kinase inhibitors
AU2013302319A1 (en) * 2012-08-17 2015-02-26 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
CN104736533B (zh) * 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
WO2015157360A1 (en) 2014-04-08 2015-10-15 Abbvie Inc. Processes to make protein kinase inhibitors
US20170197980A1 (en) * 2014-06-25 2017-07-13 Abbvie Inc. N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
AU2020291464A1 (en) * 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
US12624049B2 (en) 2020-05-11 2026-05-12 University Health Network Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-z-yl)thieno[2.3-b]pyridin-6(7H)-one

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1188529A (en) 1966-06-09 1970-04-15 Wellcome Found Pyramidine Derivatives
US4357535A (en) 1980-04-30 1982-11-02 North American Philips Corporation Apparatus for inspecting hand-held articles and persons carrying same
GB8307154D0 (en) 1983-03-15 1983-04-20 Mk Electric Ltd Terminals
US4767766A (en) 1987-01-30 1988-08-30 Merck & Co., Inc. Derivatives of 3-hydroxyazabenzo(B)thiophene useful as 5-lipoxygenase inhibitors
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0436810Y2 (pt) 1987-12-29 1992-08-31
US4843949A (en) 1988-08-29 1989-07-04 Pneumo Abex Corporation Fluid control valve with variable pressure gain
GB8912498D0 (en) 1989-05-31 1989-07-19 De Beers Ind Diamond Diamond growth
EP0438261A3 (en) 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69431173T2 (de) 1993-06-16 2003-05-08 E.I. Du Pont De Nemours And Co., Wilmington Mit Wasser reinigbare Dickfilmpastenzusammensetzung
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
DE29511756U1 (de) 1995-07-20 1995-09-28 Ferco International Usine de Ferrures de Bâtiment S.A.R.L., Sarrebourg Flügelseitiges Ecklagerbeschlagteil für Drehkippfenster
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE19620508A1 (de) 1996-05-22 1997-11-27 Hoechst Ag Schwefelenthaltende heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
CN1118462C (zh) 1997-04-22 2003-08-20 神经研究公司 取代的苯基衍生物、其制备方法以及用途
CA2306870A1 (en) 1997-10-20 1999-04-29 David Michael Goldstein Bicyclic kinase inhibitors
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
WO2001019828A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP1342363B9 (en) 2000-12-15 2012-09-12 BRITISH TELECOMMUNICATIONS public limited company Transmission and reception of audio and/or video material
CA2438586A1 (en) 2001-03-14 2002-09-19 Eli Lilly And Company Retinoid x receptor modulators
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
JP2005508904A (ja) 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
US20050019424A1 (en) 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2004064778A2 (en) 2003-01-17 2004-08-05 Merck & Co. Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10303311A1 (de) * 2003-01-28 2004-07-29 Basf Ag Addukte auf Basis cyclischer Verbindungen und ihre Verwendung als Gerbstoffe und Konservierungsmittel
EP1620094A4 (en) 2003-05-06 2010-04-28 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007005730A (es) 2004-11-11 2007-10-04 Achillion Pharmaceuticals Inc Inhibidores de la formacion de capsida del vih-1: ureas sustituidas de arilo aminometil tiazol y analogos de las mismas.
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
US7566721B2 (en) 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
JP2009504759A (ja) 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ１０阻害剤
EP1951728A4 (en) 2005-11-04 2011-04-20 Glaxosmithkline Llc THIENOPYRIDINES AS INHIBITORS OF B-RAF KINASE
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
CA2658764A1 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
KR101639642B1 (ko) * 2008-12-05 2016-07-14 애브비 바하마스 리미티드 암 치료에 사용하기 위한 키나제 억제제로서의 티에노［3,2-ｃ］피리딘 유도체

Also Published As

Publication number Publication date
PE20110830A1 (es) 2011-12-14
IL212716A (en) 2013-10-31
MY179042A (en) 2020-10-26
US8722890B2 (en) 2014-05-13
IL212716A0 (en) 2011-07-31
AR074481A1 (es) 2011-01-19
TW201431862A (zh) 2014-08-16
PA8852401A1 (es) 2010-07-27
MX2011005943A (es) 2011-06-27
DOP2011000153A (es) 2011-06-30
EP2373662B1 (en) 2014-09-24
KR101639642B1 (ko) 2016-07-14
US20100144783A1 (en) 2010-06-10
CO6382131A2 (es) 2012-02-15
CA2743592A1 (en) 2010-06-10
UY32291A (es) 2010-07-30
CN102239171B (zh) 2014-06-11
WO2010065825A3 (en) 2010-08-26
AU2009322270A1 (en) 2011-07-14
RU2480472C2 (ru) 2013-04-27
UA103351C2 (uk) 2013-10-10
CL2011001312A1 (es) 2011-10-07
TW201026706A (en) 2010-07-16
EP2373662A2 (en) 2011-10-12
US20120309783A1 (en) 2012-12-06
HK1159628A1 (en) 2012-08-03
JP5588458B2 (ja) 2014-09-10
CN102239171A (zh) 2011-11-09
RU2012156958A (ru) 2014-06-27
TWI441827B (zh) 2014-06-21
WO2010065825A2 (en) 2010-06-10
TWI500621B (zh) 2015-09-21
ECSP11011172A (es) 2011-08-31
ES2524966T3 (es) 2014-12-16
AU2009322270B2 (en) 2014-12-18
JP2012511016A (ja) 2012-05-17
RU2011127451A (ru) 2013-01-10
KR20110091577A (ko) 2011-08-11
NZ592714A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
HUS000513I2 (hu) Relebaktám vagy monohidrátja
DK2245130T3 (da) Ts23 -alpha-amylasevarianter med ændrede egenskaber
BRPI0921327A2 (pt) Combinação de herbicida-protetor
EP2486509A4 (en) PLATFORM SECURITY
BRPI0913642A2 (pt) produtos de combinação
BRPI0922728A2 (pt) combinação de herbicida-antídoto
DK2240506T3 (da) IAP inhibitorer
FI20085696A0 (fi) Liesiturvajärjestelmä
DK2163699T3 (da) Forbindelsesprofil
ES1069811Y (es) Apero manual
BRPI0921952A2 (pt) perfil de vedação
IT1391542B1 (it) Cassaforte
DE502009000386D1 (de) Sicherungseinrichtung
DK2326372T3 (da) Sikkerhedssprøjte
ATE537394T1 (de) Sicherheitsventil
ES1068411Y (es) Cerradura de seguridad
ES1068438Y (es) Tarima alistonada
TH0901005475A (th) สารยับยั้งไคเนสซึ่งมีโพรไฟล์ด้านความปลอดภัยของ cyp ที่ดีขึ้น
ITLT20080001A1 (it) Valvola di sicurezza
UA17414S (uk) Профіль
UY3794Q (es) Perfil
UY3795Q (es) Perfil
UA17416S (uk) Профіль
UA17415S (uk) Профіль
UY3793Q (es) Perfil

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: ABBOTT LABORATORIES (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: ABBOTT LABORATORIES (US)

B25B Requested transfer of rights rejected

Owner name: ABBOTT LABORATORIES (US)